5-Amino-1MQ and NNMT Research: Metabolic Pathways and the Human Evidence Gap
The short answer
5-Amino-1MQ is a small-molecule inhibitor used in research on nicotinamide N-methyltransferase (NNMT). It is not a peptide. NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide and linking nicotinamide metabolism with cellular methyl-donor balance.
Published 5-Amino-1MQ findings are primarily from cells and animal models. Reports of reduced fat mass or altered glucose-related measures in diet-induced-obese mice are not clinical evidence of weight loss in humans.
Why NNMT is studied
NNMT expression varies by tissue and metabolic context. Because its reaction uses nicotinamide and S-adenosylmethionine, researchers have investigated whether changing NNMT activity influences NAD-related metabolism, methylation potential, adipose biology and energy expenditure.
An enzyme’s association with a pathway does not mean that inhibiting it will produce one predictable whole-body effect across species or populations.
What early inhibitor studies found
A 2018 study described selective, cell-permeable NNMT inhibitors and reported metabolic changes in diet-induced-obese mice, including lower body weight and white-adipose mass under the tested conditions. This established a preclinical tool and hypothesis—not a human treatment.
Later animal research
Subsequent mouse studies examined 5-Amino-1MQ alongside dietary changes and in models of obesity-associated metabolic dysfunction. A 2024 study reported dose-related changes in fat-mass gain, glucose tolerance, insulin measures and liver histology in mice.
Study sponsorship, model selection, exposure route, duration and endpoints all affect interpretation. Multiple favourable endpoints in one animal programme do not replace controlled human trials.
Weight change is an outcome, not a mechanism label
Terms such as “NNMT inhibitor” or “metabolic research compound” describe a target or research use. They do not establish that a manufactured material causes safe, durable weight loss. Human outcomes require evidence on efficacy, adverse effects, pharmacokinetics, interactions and long-term consequences.
Material identity matters
5-Amino-1MQ is sometimes grouped with peptides in research catalogues, but chemically it is a small molecule. Analytical methods, salt form, counter-ion, assay and impurity profile should be appropriate to the actual chemical material. Peptide-specific assumptions should not be applied automatically.
Key points
- 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide.
- NNMT connects nicotinamide and methyl-donor metabolism.
- Reported weight and metabolic findings are from animal models.
- Animal weight loss is not proof of human efficacy or safety.
- Chemical identity, form and assay require material-specific evidence.
What this article does not establish
This article does not establish that 5-Amino-1MQ causes weight loss, improves metabolic health or treats any condition in people. It does not establish that an AURAPEP material is equivalent to a cited research compound, safe, effective or suitable for human use.
References
- Neelakantan H, et al. Selective and membrane-permeable small-molecule inhibitors of NNMT reverse high-fat-diet-induced obesity in mice. Biochem Pharmacol. 2018. https://pubmed.ncbi.nlm.nih.gov/29155147/
- Sampson CM, et al. Combined NNMT inhibition and diet modification in diet-induced-obese mice. Sci Rep. 2021. https://pubmed.ncbi.nlm.nih.gov/33707534/
- Dimet-Wiley A, et al. Reduced-calorie diet combined with NNMT inhibition in diet-induced-obese mice. J Nutr Biochem. 2022. https://pubmed.ncbi.nlm.nih.gov/35013352/
- Babula JAJ, et al. NNMT inhibition mitigates obesity-associated metabolic dysfunction in mice. Diabetes Obes Metab. 2024. https://pubmed.ncbi.nlm.nih.gov/39161060/